Intranasal etripamil for rapid treatment of paroxysmal supraventricular tachycardia

References

• Rehorn M, Sacks NC, Emden MR, et al. Prevalence and incidence of patients with paroxysmal supraventricular tachycardia in the United States. J. Cardiovasc. Electrophysiol. 2021;32(8):2199–2206. doi:10.1111/jce.15109
   PubMed Web of Science ®Google Scholar
• Murman DH, McDonald AJ, Pelletier AJ, Camargo CA. U.S. emergency department visits for supraventricular tachycardia, 1993–2003. Acad. Emerg. Med. 2007;14(6):578–581. doi:10.1197/j.aem.2007.01.013
   PubMed Web of Science ®Google Scholar
• Ungvari Z, Yabluchanskiy A, Tarantini S, et al. Repeated Valsalva maneuvers promote symptomatic manifestations of cerebral microhemorrhages: implications for the pathogenesis of vascular cognitive impairment in older adults. Geroscience. 2018;40(5–6):485–496. doi:10.1007/s11357-018-0044-9
   PubMed Web of Science ®Google Scholar
• Mariaca AF, Valdueza JM, Gaebel C, Gomez-Choco M. Simultaneous transient global amnesia and right MCA stroke after Valsalva manoeuvre. BMJ Case Rep. 2017;2017:bcr-2016-218990. doi:10.1136/bcr-2016-218990
   PubMedGoogle Scholar
• Walsh T, Clinch D, Costelloe A, et al. Carotid sinus massage – how safe is it? Age Ageing. 2006;35(5):518–520. doi:10.1093/ageing/afl057
   PubMed Web of Science ®Google Scholar
• Smith GD, Fry MM, Taylor D, et al. Effectiveness of the Valsalva manoeuvre for reversion of supraventricular tachycardia. Cochrane Database Syst. Rev. 2015;2015(2):CD009502. doi:10.1002/14651858.CD009502.pub3
   PubMedGoogle Scholar
• Stambler BS, Ip JE, Plat F, et al. PO-641-08 Very low efficacy of vagal maneuvers in terminating paroxysmal supraventricular tachycardia: results from the NODE-301 study. Heart Rhythm. 2022;19(5):S211. doi:10.1016/j.hrthm.2022.03.152
   Google Scholar
• Appelboam A, Reuben A, Mann C, et al. Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial. Lancet. 2015;386(10005):1747–1753. doi:10.1016/S0140-6736(15)61485-4
   PubMed Web of Science ®Google Scholar
• Alboni P, Tomasi C, Menozzi C, et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J. Am. Coll. Cardiol. 2001;37(2):548–553. doi:10.1016/S0735-1097(00)01128-1
   PubMed Web of Science ®Google Scholar
• Lim SH, Anantharaman V, Teo WS, Chan YH. Slow infusion of calcium channel blockers compared with intravenous adenosine in the emergency treatment of supraventricular tachycardia. Resuscitation. 2009;80(5):523–528. doi:10.1016/j.resuscitation.2009.01.017
   PubMed Web of Science ®Google Scholar
• Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur. Heart J. 2020;41(5):655–720. doi:10.1093/eurheartj/ehz467
   PubMed Web of Science ®Google Scholar
• Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia. Circulation. 2016;133(14):e471–e505.
   PubMed Web of Science ®Google Scholar
• Weintraub S, Frishman WH. A novel calcium channel blocker: etripamil: what is the future of intranasal drug delivery in the treatment of cardiac arrhythmias? Cardiol. Rev. 2021;29(5):253–258. doi:10.1097/CRD.0000000000000362
   PubMed Web of Science ®Google Scholar
• Bathina M, Mickelsen S, Brooks C et al. Radiofrequency catheter ablation versus medical therapy for initial treatment of supraventricular tachycardia and its impact on quality of life and healthcare costs. Am. J. Cardiol. 1998;82(5):589–593. doi:10.1016/S0002-9149(98)00416-0
   PubMed Web of Science ®Google Scholar
• Weerasooriya R, Jaïs P, le Heuzey J-Y, et al. Cost analysis of catheter ablation for paroxysmal atrial fibrillation. Pacing Clin. Electrophysiol. 2003;26(1P2):292–294. doi:10.1046/j.1460-9592.2003.00035.x
   PubMedGoogle Scholar
• Cheng CH, Sanders GD, Hlatky MA, et al. Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia. Ann. Intern. Med. 2000;133(11):864–876. doi:10.7326/0003-4819-133-11-200012050-00010
   PubMed Web of Science ®Google Scholar
• Stambler BS, Dorian P, Sager PT, et al. Etripamil nasal spray for rapid conversion of supraventricular tachycardia to sinus rhythm. J. Am. Coll. Cardiol. 2018;72(5):489–497. doi:10.1016/j.jacc.2018.04.082
   PubMed Web of Science ®Google Scholar
• Stambler BS, Plat F, Wight D et al. Electrophysiological mechanism of action of inhaled etripamil on AV nodal refractoriness and conduction in subjects with paroxysmal supraventricular tachycardia (PSVT) in the NODE-1 trial. Heart Rhythm. 2019;16(5):S214.
   Google Scholar
• Choe WC, Sundaram S, Boorman C, et al. High-density mapping of the slow pathway in a patient with atrioventricular nodal reentry given intranasal etripamil during the NODE-1 study. Heart Rhythm Case Rep. 2017;3(10):479–482. doi:10.1016/j.hrcr.2017.07.011
   PubMedGoogle Scholar
• Chu GS, Gupta D. Update on etripamil nasal spray for the at-home treatment of acute paroxysmal supraventricular tachycardia. Heart Int. 2021;15(1):2–6. doi:10.17925/HI.2021.15.1.2
   PubMed Web of Science ®Google Scholar
• Stambler BS, Plat F, Sager PT, et al. First randomized, multicenter, placebo-controlled study of self-administered intranasal etripamil for acute conversion of spontaneous paroxysmal supraventricular tachycardia (NODE-301). Circ. Arrhythm Electrophysiol. 2022;15(12):e010915. doi:10.1161/CIRCEP.122.010915
   PubMed Web of Science ®Google Scholar
• Ip JE, Coutu B, Bennett MT, et al. Etripamil nasal spray for conversion of repeated spontaneous episodes of paroxysmal supraventricular tachycardia during long-term follow-up: results from the NODE-302 Study. J. Am. Heart Assoc. 2023;12(19):e028227. doi:10.1161/JAHA.122.028227
   PubMed Web of Science ®Google Scholar
• Stambler B, Camm AJ, Alings M, et al. Self-administered etripamil for termination of spontaneous paroxysmal supraventricular tachycardia: primary analysis from the RAPID study [Internet]. American Heart Association Scientific Sessions November 2022. 2022. Available from: https://www.acc.org/education-and-meetings/image-and-slide-gallery/~/media/ac4bc002d30f4b6ab0a51996881ff5d0.pdf
   Google Scholar
• Milestone Pharmaceuticals Inc. Safety study of etripamil nasal spray for patients with paroxysmal supraventricular tachycardia. NODE-303. https://investors.milestonepharma.com/news-releases/news-release-details/milestone-pharmaceuticals-progresses-clinical-and-regulatory
   Google Scholar
• Milestone Pharmaceuticals Inc. Clinical trials: etripamil nasal spray in patients with paroxysmal supraventricular tachycardia. Available from: https://clinicaltrials.gov/ct2/show/NCT04952610
   Google Scholar
• Stambler BS, Plat F, Sager PT, et al. Rationale for and design of a multicenter, placebo-controlled, phase 3 study to assess efficacy and safety of intranasal etripamil for the conversion of paroxysmal supraventricular tachycardia. Am. Heart J. 2022;253:20–29. doi:10.1016/j.ahj.2022.06.005
   PubMed Web of Science ®Google Scholar
• Camm AJ, Piccini JP, Alings M, et al. Multicenter, phase 2, randomized controlled study of the efficacy and safety of etripamil nasal spray for the acute reduction of rapid ventricular rate in patients with symptomatic atrial fibrillation (ReVeRA-201). Circ. Arrhythm Electrophysiol. 2023;16(12):639–650. doi:10.1161/CIRCEP.123.012567
   PubMed Web of Science ®Google Scholar
• Russo E, Giombi F, Paoletti G, et al. Use, abuse, and misuse of nasal medications: real-life survey on community pharmacist's perceptions. J. Pers. Med. 2023;13(4):579. doi:10.3390/jpm13040579
   PubMed Web of Science ®Google Scholar